Subscribe To
Inhibikase therapeutics to report fourth quarter and full-year 2022 financial results on march 31, 2023
BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmac...
March 23, 2023, 5:15 pm
Biohaven (bhvn) acquires dual inhibitor for brain disorders
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical ...
March 23, 2023, 12:13 pm
Nuvalent to present alkove-1 trial in progress poster for nvl-655 at the european lung cancer congress (elcc 2023)
CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating preci...
March 23, 2023, 6:30 am
Deciphera pharmaceuticals: intrigue phase 3 shows substantial benefit
Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltini...
March 18, 2023, 5:21 am
Predictive oncology and cancer research horizons partner up to pursue development of cancer drugs
Predictive Oncology Inc. (NASDAQ:POAI) and Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cance...
March 17, 2023, 9:23 am
Why is histogen (hsto) stock up 37% today?
Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhi...
March 17, 2023, 8:37 am
Celcuity to present preclinical data on therapeutic effects of gedatolisib in gynecological cancer models at aacr annual meeting 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted...
March 15, 2023, 7:35 pm
Kinnate biopharma inc. to report first clinical data for its investigational pan-raf inhibitor, exarafenib (kin-2787), in an oral presentation at the aacr 2023 annual meeting
SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision onco...
March 14, 2023, 6:09 pm
Nuvalent to present new preclinical data on alk-selective inhibitor nvl-655 at aacr annual meeting 2023
CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating preci...
March 14, 2023, 5:59 pm
Aptose to report fourth quarter and full year 2022 financial results and hold conference call on thursday, march 23, 2023
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology compan...
March 9, 2023, 4:05 pm
Tx rx systems to appear at iwce 2023 exhibit hall
ANGOLA, N.Y., March 09, 2023 (GLOBE NEWSWIRE) — TX RX Systems, an industry leader in the Land Mobile Radio (LMR) market, is pleased to announce the ...
March 9, 2023, 3:51 pm
Enanta pharmaceuticals to present new data for edp-235, its 3cl protease inhibitor, in development as an oral, once-daily treatment for covid-19, at the 36th international conference on antiviral rese
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc....
March 8, 2023, 8:51 am
Enanta pharmaceuticals to present new data for edp-235, its 3cl protease inhibitor, in development as an oral, once-daily treatment for covid-19, at the 36th international conference on antiviral rese
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc....
March 8, 2023, 8:51 am
Exchange rate has positive effect on australian gold industry – surbiton
Although US dollar gold prices declined sharply during February to the lowest figures for almost two years, Australian gold producers were broadly shi...
March 6, 2023, 9:59 am
Stable cad plaque morphology improved by pcsk9 inhibitors: yellow iii
Intensified LDL-lowering upped fibrous cap thickness on OCT and cut lipid burden on NIRS. Next up: biomarkers to predict effects. Read Full Story at s...
March 4, 2023, 9:59 pm
Pd-1/pd-l1 inhibitors market to record a cagr of 9.6% & to reach a valuation of usd 123.3 billion by 2033 – exclusive report by future market insights, inc.
Increasing Government Cancer-fighting Measures, Growing Healthcare Expenses, and Increased Public Awareness are anticipated to Propel the Industry Ahe...
March 3, 2023, 11:30 am
Pliant therapeutics' bexotegrast shows promise for idiopathic pulmonary fibrosis
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related d...
March 3, 2023, 10:48 am
Fmls23 has officially kicked off – dates, venue and more
The Finance Magnates London Summit (FMLS) will be returning for its 11th year, returning on November 20-22, 2023 at Old Billingsg...
March 1, 2023, 10:50 am
Cogent biosciences: bezuclastinib's potential in treating gastrointestinal stromal tumors
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointesti...
February 28, 2023, 2:17 am
Revolution medicines reports fourth quarter and full year 2022 financial results and update on corporate progress
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional...
February 27, 2023, 9:05 pm